The EMT-induced lncRNA NR2F1-AS1 positively modulates NR2F1 expression and drives gastric cancer via miR-29a-3p/VAMP7 axis

Dandan Li, Mengjie Xu, Zidi Wang, Pan Huang, Congcong Huang, Zhen Chen, Gaijuan Tang, Xingji Zhu, Mengyu Cai and Shanshan Qin

© The Author(s) 2022

Deregulated lncRNAs play critical roles in tumorigenesis and tumor progression. NR2F1-AS1 is an antisense lncRNA of NR2F1. However, the biological function of NR2F1-AS1 in gastric cancer (GC) remains largely unclear. In this study, we revealed that NR2F1-AS1 and NR2F1 were both positively correlated with the degree of malignancy and predicted poor prognosis in two independent GC cohorts. Besides, NR2F1-AS1 and NR2F1 can respond to Epithelial-to-mesenchymal transition (EMT) signaling in GC, since their expression was increased by TGF-beta treatment and decreased after stable overexpression of OVOL2 in GC cell lines. NR2F1-AS1 and NR2F1 were highly co-expressed in pan-tissues and pan-cancers. Depletion of NR2F1-AS1 compromised the expression level of NR2F1 in GC cells. Furthermore, NR2F1-AS1 knockdown inhibited the proliferation, migration, invasion and G1/S transition of GC cells. More importantly, transcriptome sequencing revealed a novel ceRNA network composed of NR2F1-AS1, miR-29a-3p, and VAMP7 in GC. The overexpression of VAMP7 predicted poor prognosis in GC. Rescue assay confirmed that NR2F1-AS1 promotes GC progression through miR-29a-3p/VAMP7 axis. Our finding highlights that the aberrant expression of NR2F1-AS1 is probably due to the abnormal EMT signaling in GC. LncRNA NR2F1-AS1 plays crucial roles in GC progression by modulating miR-29a-3p/VAMP7 axis, suggesting that NR2F1-AS1 may serve as a potential therapeutic target in GC.

Cell Death and Disease (2022) 13:84; https://doi.org/10.1038/s41419-022-04540-2

INTRODUCTION

Gastric cancer (GC) is a heterogeneous tumor with the fourth highest mortality rate worldwide [1]. According to the latest global cancer burden data report released by the International Agency for Research on Cancer (IARC), there will be approximately 1.089 million new cases of gastric cancer and 769,000 deaths worldwide in 2020 [2, 3]. Due to the inconvenience of early diagnosis of GC, many patients are diagnosed at advanced stages [4]. Therefore, it is urgent and necessary to develop new biomarkers or strategies to improve the early diagnosis of GC.

Metastasis is the leading cause of cancer-related deaths, especially in stomach cancer. In 2015, Cristescu et al. have reported that GC patients with EMT molecular subtype possess worst prognosis [5]. Similarly, in 2018, Oh et al. also found that GC patients with mesenchymal phenotype possessed poorer prognosis than GC patients with intestinal phenotype [6]. Tumor metastasis are the result of a complex process that involves local invasion, intravasation, transport, extravasation, micro-metastasis formation and colonization [7]. The metastatic cascade is a multifaceted process, in which EMT mediates the initial transformation from benign to invasive carcinoma [8]. EMT, an evolutionarily conserved program of cellular plasticity, allows polarized, immotile epithelial cells to loosen their cell-cell adhesion, detach from neighboring cells, and to convert into motile mesenchymal cells [9]. The occurrence of EMT requires a variety of extracellular signals, such as transforming growth factor, fibroblast growth factor, hepatocyte growth factor, and epidermal growth factor and chemokines [10]. Once the EMT program is started, remarkable changes would be observed in the expression of the EMT-related genes [11, 12]. These EMT-related genes eventually have a profound effect on cell morphology and function [13, 14]. However, most of the existing research focuses on the coding genes caused by EMT, and the biological functions of EMT-related lncRNA are relatively rarely reported.

In this study, we identified an antisense lncRNA NR2F1-AS1 that induced by EMT in GC. NR2F1-AS1 was positively correlated with the degree of malignancy and predicted poor prognosis in two independent GC cohorts. Transcriptome sequencing revealed a novel ceRNA network composed of NR2F1-AS1, miR-29a-3p, and VAMP7 in GC. In vitro experiments confirmed that NR2F1-AS1 promotes GC metastasis through the miR-29a/VAMP7 signal axis. Therefore, targeting the NR2F1-AS1/miR-29a-3p/VAMP7 axis could be a new potential strategy for the treatment of GC.
NR2F1-AS1 and NR2F1 are clinically correlated with poor prognosis in GC

NR2F1-AS1 is an antisense lncRNA (head-to-head) of NR2F1, also known as COUP Transcription Factor I (COUPTF1, Fig. 1a). To explore the biological function of NR2F1 and NR2F1-AS1 in GC, we first analyzed the correlation between gene expression and the clinical characteristics and prognosis of GC. Two independent large cohorts of GC were included in our study, one is the GSE62254 cohort (<i>n</i> = 300) and the other is the TCGA cohort (<i>n</i> = 373).

After clinical analysis in GSE62254 cohort, we found that NR2F1 and NR2F1-AS1 were highly expressed in diffuse GC (Fig. 1b). GC patients with relatively high degree of malignancy had higher expression of NR2F1 and NR2F1-AS1 (Fig. 1c–e). Besides, GC tissues with Perineural Invasion (PNI) or distant metastasis tended to possess relatively high expression of NR2F1 and NR2F1-AS1 (Fig. 1f, g). Moreover, GC patients with higher expression of NR2F1-AS1 and NR2F1 had a shorter OV time and DFS time (Fig. 1h, i). Similarly, we also noted that the expression level of NR2F1 and NR2F1-AS1 showed a significant correlation with the histopathological type, malignant progression, poor differentiation, and poor prognosis of GC patients from TCGA cohort (Fig. 2a–h). Based on the clinical analysis in two independent GC cohorts, NR2F1-AS1 and NR2F1 are potential promising biomarkers that closely associated with malignant progression and prognosis of GC patients. NR2F1 and NR2F1-AS1 might function oncogenic roles in GC.

NR2F1-AS1 and NR2F1 are EMT-induced genes in GC

According to the differences of molecular subtypes, GC could be further divided into four subtypes, including MSS/TP53<sup>−</sup>, MSS/TP53<sup>+</sup>, MSI, and MSS/EMT subtypes [15]. Our previous publication has identified MAGI2-AS3 as an EMT-related lncRNA in GC [1]. Herein, we confirmed that both NR2F1 and NR2F1-AS1 are EMT-related genes using the same method, since NR2F1 and NR2F1-AS1 were highly expressed in the EMT subtype of GC tissues (Fig. 3a). In addition, correlation analysis based on the gene expression of TCGA cohort showed that the expression of NR2F1 and NR2F1-AS1 were positively correlated with the expression of mesenchymal biomarker genes, but negatively correlated with the expression of epithelial genes in GC (Fig. 3b, c). These results together suggested that both NR2F1 and NR2F1-AS1 were related to EMT signaling in GC.

To further determine whether NR2F1 and NR2F1-AS1 could respond to the EMT signaling, we observed the expression alteration of NR2F1-AS1 and NR2F1 in GC cells with epithelial state or mesenchymal state. TGF-beta is known to be a critical...
extracellular signal that initiates EMT. Herein, we constructed mesenchymal GC cells by treatment with exogenous TGF-beta (Fig. 3d). After detecting the gene expression by qRT-PCR, we found that both NR2F1 and NR2F1-AS1 were significantly increased after TGF-beta treatment (Fig. 3e, f).

Transcription factor OVOL2 functions as an inducer of MET [16]. Thus, we constructed epithelial-phenotype GC cells by over-expression of OVOL2. According to the qRT-PCR and RNA-seq analysis, the GC cell lines with stable overexpression of OVOL2 were successfully constructed by lentiviral method (Fig. 3g, h).

After comparison of gene expression level in GC cell line with/without overexpression of OVOL2 by RNA-seq and qRT-PCR assay, the expression of NR2F1-AS1 and NR2F1 were both found to be sharply declined in the GC cells overexpression of OVOL2 (Fig. 3i–k), indicating that both NR2F1-AS1 and NR2F1 were EMT induced genes.

NR2F1-AS1 positively regulates the expression of NR2F1 in GC

The quantitative transcriptomics of the Human Protein Atlas (HPA) project provides the tissue specificity of all protein-coding genes and most lncRNAs. According to HPA dataset, NR2F1-AS1 and NR2F1 showed similar tissue-specific expression patterns (Fig. 4a). Pan-tissue and Pan-cancer analysis based on the RNA-seq data in HPA, GTEx and TCGA datasets together showed that NR2F1-AS1 was highly co-expressed with NR2F1 in human tissues (Fig. 3g, h). In normal stomach tissues and GC tissues, NR2F1 and NR2F1-AS1 were also highly co-expressed as expected (Fig. 4a–g).

In order to understand the co-expression between NR2F1 and NR2F1-AS1, we knocked down the expression of NR2F1-AS1 and overexpressed NR2F1 in GC cell lines, respectively. The NR2F1-AS1 has multiple transcript types due to alternative splicing. According to the difference of their last exon, NR2F1-AS1 transcripts could be divided into two groups. Herein, we designed 2 specific siRNAs for each group of NR2F1-AS1 transcript to avoid off-target effect (Fig. 4h). The qRT-PCR assay verified that NR2F1-AS1 was successfully knocked down in GC cell lines (Fig. 4i). Then, we observed a significant decline in the expression of NR2F1 after knockdown of NR2F1-AS1 in GC cell lines (Fig. 4j).

Given that NR2F1 acts as a transcription factor, we also speculated NR2F1-AS1 may be able to be regulated by NR2F1. Hence, we constructed stably overexpressed of NR2F1 by lentiviral method (Fig. 4k). However, according to the RNA-seq analysis, we didn’t observe significant changes in the expression of NR2F1-AS1 in the GC cells overexpressing NR2F1, suggesting NR2F1 cannot regulate NR2F1-AS1 expression in GC. Taken together, the co-expression between NR2F1 and NR2F1-AS1 might be partly due to the positive regulation of NR2F1 by NR2F1-AS1.

NR2F1-AS1 promotes proliferation and invasion of GC cells in vitro

Clinical analysis implied NR2F1-AS1 functioned as an oncogene in GC. Thus, we used loss-of-function study to further verify the effect of NR2F1-AS1 on the biological behavior of GC cells. According to the NR2F1-AS1 knockdown efficiency, we selected two optimal siRNAs for these in vitro experiments. Cell proliferation assay showed that knockdown of NR2F1-AS1 suppressed the cell growth of GC cell lines (Fig. 5a). Transwell assay indicated that knockdown of NR2F1-AS1 significantly inhibited the cell invasion of GC cell lines (Fig. 5b, c). The wounding healing assay showed that knockdown of NR2F1-AS1 hindered the cell migration of GC cell lines (Fig. 5d, e). Given NR2F1-AS1 knockdown had a significant effect on cell growth, we further investigated the role of NR2F1-AS1 in cell cycle progression of GC cells (Fig. 5f). Knockdown of NR2F1-AS1 caused an obvious G1 arrest in GC cells due to the prolonged G1/S transition, indicating that NR2F1-AS1 may promote GC proliferation through accelerating G1/S transition of GC cells. However, although knockdown of NR2F1-AS1 unexpectedly repressed the early apoptosis and the late apoptosis of GC cells (Fig. 5i), it
should be pointed out that knockdown of NR2F1-AS1 only inhibited the apoptosis of about 7–9% of GC cells, suggesting that NR2F1-AS1 regulates GC cell apoptosis locally but not extensively.

**NR2F1-AS1 promotes GC progression through maintaining VAMP7 overexpression**

To explore the molecular mechanism of the cancer-promoting effect of NR2F1-AS1, transcriptome sequencing (GSE183538) was performed in the NR2F1-AS1 depleted GC cells. Two different siRNAs were chosen to avoid target-off effect. After RNA-seq analysis, the top 100 genes that profoundly affect by NR2F1-AS1 knockdown was shown in the heat plot (|Log2FC| > 1, Fig.6a). The volcano plot shows that knockdown of NR2F1-AS1 had the most significant effect on the expression of VAMP7 gene (Fig. 6b). Besides, the RNA-seq, qRT-PCR and immunoblotting assay together showed that the mRNA level and protein level of VAMP7 were significantly decreased after knockdown of NR2F1-AS1 in GC cell lines (Fig. 6c–e). In addition, NR2F1-AS1 showed a significant co-expression with VAMP7 in normal stomach tissues (Fig. 6f). These results together suggested that NR2F1-AS1 played critical roles in regulating VAMP7 expression in GC.

The biological function of VAMP7 in GC remains largely unknown to date. To verify whether NR2F1-AS1 promotes GC progression by regulating the expression of VAMP7, we first investigated the expression of VAMP7 in normal and stomach cancer tissues. The results showed that VAMP7 was overexpressed in GC (Fig. 6g). To understand the clinical significance of VAMP7 overexpression, the survival curves were analyzed based on the GSE62254 cohort. The results showed that overexpression of VAMP7 predicted poor prognosis in GC (Fig. 6h). These results implied VAMP7 functions as an oncogene in GC. In other words, NR2F1-AS1 might promote GC progression through maintaining VAMP7 overexpression. To verify this possibility, we conducted rescue experiments in GC cell lines. The rescue experiments showed that knockdown of VAMP7 alone significantly inhibited...
the growth of GC cells, and knockdown of VAMP7 and NR2F1-AS1 deepened the inhibition of cell growth by NR2F1-AS1 knockdown alone (Fig. 6i).

**NR2F1-AS1 functions as a ceRNA to regulate VAMP7 expression by sponging miR-29a**

The biological function of lncRNA is closely related to its subcellular location [17]. Therefore, RNA Fish assays was conducted in GC cells. The results revealed that NR2F1-AS1 transcripts were distributed in the nucleus and cytoplasm of SGC7901 cells (Fig. 7a). Besides, the nuclear-cytoplasmic RNA fractionation assay followed by qRT-PCR showed that more than half of NR2F1-AS1 transcripts were located in the cytoplasm of GC cell lines (Fig. 7b). GO analysis showed that NR2F1-AS1 mainly functions in cytoplasm (Fig. 7c).

Emerging studies have reported the biological function of NR2F1-AS1 in cancers. Most of the studies showed that NR2F1-AS1 promoted tumor progression by function as a ceRNA in breast cancer [18], thyroid cancer [19], and lung cancer [20]. Our subcellular localization and GO analysis also suggested that NR2F1-AS1 had the basic conditions for exerting ceRNA roles. Therefore, we analyzed the miRNAs that might be sponged by NR2F1-AS1 and the miRNAs that predicted to target VAMP7. After taking the intersection, we found that NR2F1-AS1 may regulate VAMP7 expression by sponging miR-29a/b/c and miR-218 (Fig. 7d). However, survival analysis showed that miR-218 predicted poor prognosis in GC, while only miR-29a predicted favorable prognosis in GC (Fig. 7e). Besides, increasing studies have reported the tumor-suppressive role of miR-29a-3p in GC. Knockdown of NR2F1-AS1 significantly increased the expression level of miR-29a-3p in GC cell lines (Fig. 7f). Taken together, we considered NR2F1-AS1 might regulate VAMP7 expression by sponging miR-29a-3p in GC.

Therefore, we investigated the effect of miR-29a-3p on the expression level of VAMP7 in GC. The results showed that VAMP7 was downregulated in the GC cells transfecting with miR-29a mimics, but was upregulated in the GC cells transfecting with miR-29a inhibitors (Fig. 7g, h). Moreover, dual-luciferase reporter assay and rescue assay together confirmed that miR-29a-3p repressed cell proliferation by targeting VAMP7 in GC (Fig. 7i, j). Additionally, both NR2F1-AS1 and VAMP7 showed a significant negative correlation with miR-29a in the TCGA cohort (Fig. 7k, l), suggesting there is a novel ceRNA network composed of NR2F1-AS1, miR-29a-3p and VAMP7 in GC.

In summary, lncRNA NR2F1-AS1 acts as a sponge for miR-29a-3p and promotes GC progression through regulating miR-29a-3p/VAMP7 axis. Additionally, NR2F1-AS1 was positively regulated by EMT signaling. Once abnormal EMT signaling occurs, it will lead to a significant up-regulation of NR2F1-AS1, leading to the deregulated ceRNA network and aberrant VAMP7 expression, and ultimately promoting the malignant progression of GC (Fig. 8).

**DISCUSSION**

Large number of non-coding RNAs (ncRNA) and protein-coding genes have been found to be dysregulated in tumors or other diseases. In the past decades, the mechanism of dysregulated
ncRNAs has received little attention. Recently, increasing studies have reported ncRNAs can regulate tumor progression through forming ceRNA networks [21]. The components in ceRNA network are usually interrelated. Aberrant expression of any network component may derail complex regulatory circuits and ultimately result in tumorigenesis and metastasis [22]. Therefore, identification of ceRNA network is essential to understand how cancer-related genes are dysregulated, thereby improving disease prognosis. Since ceRNA network can at least partially explain how cancer-related genes are dysregulated, exploring and identifying novel ceRNA networks is essential to improve the prognosis of the disease.

In the present study, we identified a novel ceRNA network composed of NR2F1-AS1, miR-29a-3p, and VAMP7 in GC by transcriptome sequencing. Clinical analysis revealed that NR2F1-AS1 showed a significant correlation with the degree of malignancy and predicted poor prognosis in two independent GC cohorts. Loss-of-function studies indicated that NR2F1-AS1 promotes the proliferation, migration and invasion of GC cells. Similarly, VAMP7, a novel target gene of miR-29a-3p, was overexpressed and predicted poor prognosis in GC (Fig. 6g–l). Taken together, this deregulated ceRNA network plays critical roles in regulating GC progression.

Divergent lncRNAs usually co-expressed with nearby protein-coding genes [27]. On the one hand, the antisense IncRNA shares a promoter with neighboring genes, which causes them to be regulated by the same transcription factors [28]. On the other hand, emerging evidences reported that the antisense IncRNA and neighboring genes can be stabilized together by forming...
RNA–RNA duplex with the overlapping sequences of their transcripts [21, 29]. In addition, accumulating evidences showed that antisense lncRNAs can participate the transcription of nearby genes by recruiting transcription-related proteins or affecting R-loop formation, or regulating the methylation of enhancers [30–33]. Herein, we also observed a high co-expression between NR2F1-AS1 and NR2F1 in pan-cancer and pan-tissue. Given that NR2F1-AS and NR2F1 were both induced by EMT signaling (Fig. 3) and depletion of NR2F1-AS1 inhibited NR2F1 expression (Fig. 4), we considered that the co-expression between NR2F1-AS1 and NR2F1 was because they share the promoter and the transcriptional regulation of NR2F1-AS1 on NR2F1. Interestingly, a recent study has reported that NR2F1-AS1 expression was induced by NR2F1 in esophageal squamous cell carcinoma [34]. However, according to our qRT-PCR and RNA-seq analysis, NR2F1 over-expression has no obvious effect on the expression of NR2F1-AS1 in GC (Fig. 4K).

The relationship between EMT and NR2F1/NR2F1-AS1 has not been reported yet. Our previous work has identified a EMT-related lncRNA MAGI2-AS3 in GC [1]. In this study, we further identified both NR2F1 and NR2F1-AS1 as EMT-induced genes in GC, since NR2F1-AS1 and NR2F1 were both positively regulated by EMT signaling. Consistent with our findings, Feng et al. also reported that NR2F1 is greatly declined in GC cells that silenced Twist1, a well-known EMT-related transcription factor (EMT-TF) [35]. These findings together suggested NR2F1 was positively regulated by EMT signaling. However, after analysis of RNA-seq data of NR2F1-AS1 knockdown, we found NR2F1-AS1 knockdown has no significant effect on the expression of EMT-related biomarker genes, such as E-cadherin, Vimentin, and ZEB1. However, the specific role of NR2F1 during the EMT process remains to be further explored in GC.

CONCLUSIONS
LncRNA NR2F1-AS1 and NR2F1 predicted poor prognosis in GC. Both NR2F1-AS1 and NR2F1 are identified to be EMT-induced genes in GC. The co-expression of NR2F1 and NR2F1-AS1 may be
partly due to the regulation of NR2F1 by NR2F1-AS1. A novel ceRNA network composed of NR2F1-AS1, miR-29a-3p, and VAMP7 was identified in GC. Our finding highlights that oncogenic lncRNA NR2F1-AS1 promotes GC metastasis through regulating miR-29a/VAMP7 signal axis.

**Fig. 7** NR2F1-AS1 acted as a sponge of miR-29a-3p to regulate VAMP7 expression. a The subcellular distribution of NR2F1-AS1 in SGC7901 cells. b NR2F1-AS1 transcripts were located in cytoplasm and nucleus of GC cells. c GO analysis confirmed NR2F1-AS1 knockdown mainly function in cytoplasm. d The miRNAs that sponged by NR2F1-AS1 and miRNAs that targeting VAMP7 were predicted by miRCode and TargetScan. e The survival analysis of miR-218-5p and miR-29a/b/c-3p in GC. f Knockdown of NR2F1-AS1 significantly upregulated miR-29a-3p expression in GC cell lines. g, h VAMP7 was negatively regulated by miR-29a-3p in GC cell lines. i Luciferase reporter assay confirmed that miR-29a-3p can bind to NR2F1-AS1. j Rescue assay confirmed that miR-29a-3p inhibited the colony formation of GC cells by targeting VAMP7. k, l Both NR2F1-AS1 and VAMP7 showed a significant negative expression correlation with miR-29a-3p in the GC cohort from TCGA. **P < 0.01.

**MATERIALS AND METHODS**

Microarray data analysis of GSE62254 and pan-cancer analysis in TCGA

The gene expression data in GSE62254 used in this study was downloaded from the NCBI web server. The clinical information of GC patients in...
The total RNA in GC cells was extracted to perform RNA sequencing (RNA-seq). A total amount of 1.5 µg RNA per sample was used as input material for the RNA sample preparations. The whole step of library construction and sequencing was performed at Shanghai Lifegenes Technology Co., Ltd. The RNA-seq data was uploaded in Table S2. The GEO accession number is GSE183538.

**RNA sequencing**

The total RNA in GC cells was extracted to perform RNA sequencing (RNA-seq). A total amount of 1.5 µg RNA per sample was used as input material for the RNA sample preparations. The whole step of library construction and sequencing was performed at Shanghai Lifegenes Technology Co., Ltd. The RNA-seq data was uploaded in Table S2. The GEO accession number is GSE183538.

**Cell transfection and establishment of cell lines**

Human gastric cancer cell lines were purchased from GeneChem (Shanghai, China). The siRNAs listed in Table S1 were designed and synthesized by Genepharma (Shanghai, China). The lentiviruses for overexpression of NR2F1 and OVOL2 in GC cell lines were purchased from GeneChem (Shanghai, China). For TGF-beta treatment, 10 ng/ml recombinant TGF-β1 (cat. no. HZ-1011; Proteintech, Wuhan, China) was added to the medium. GC cells were cultured for 37 °C as usual. At the indicated time points, the cells were harvested for miRNA and protein analysis as well as for other assays.

**Subcellular location of lncRNA**

The Nuclear/cytoplasmic RNA isolation and RNA FISH assay was conducted as we previously described [21]. For Nuclear/cytoplasmic RNA isolation, cytoplasm RNA and nuclear RNA were extracted using the nuclear-cytoplasmatic separation kit (BB-36021-2, BestBio, China). After Quantitative RT-PCR, comparative ΔCt method was used to examine the relative distribution of RNA. For RNA FISH assay, the 5′FAM-NR2F1-AS1 probes were designed and synthesized by Sangon Biotech (Shanghai). After incubation and hybridization, images were taken with a confocal microscope (Zeiss).

**RNA isolation and quantitative RT-PCR**

Total RNA was extracted using Trizol reagent (Invitrogen, USA). Reverse transcription was performed to obtain cDNA by using the PrimeScript™ RT reagent Kit (Perfect Real Time, Takara). The qPCR protocol was using One Step TB Green PrimeScript™ RT-PCR Kit II (Takara) according to the manufacturer’s instructions. The qPCR analysis was conducted on Bio-Rad CFX Manager 3.1 real-time PCR system. All the primers listed in Table S1 were synthesized by Wcgene Biotech (Shanghai, China). RNU6B (U6) and ACTB were used as internal controls. Each gene was run in triplicate. Relative fold changes of gene expression were calculated using the comparative ΔΔCt method. All primers listed in Table S1 were synthesized by Wcgene Biotech (Shanghai, China).

**Western blot assay**

Gastric cancer cells were lysed in RIPA buffer added 1 mM PMSF. Approximately 100 µg of total protein was electrophoresed through 10% SDS polyacrylamide gels and were then transferred to a PVDF membrane. After blocking with 5% skimmed milk at 4 °C for 1 h, the membrane was incubated with primary antibody at 4 °C overnights. The blots were then washed and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1:10,000; Echair) for 1.5 h at room temperature. Detection was performed by using a SuperLumia ECL HRP Substrate Kit (Abbkine) and visualized using a Bio-Rad Imaging System (USA). The VAMP7 antibody used in this study was purchased from ABClonal (A18609, Wuhan, China).

**Flow cytometry assay**

After 48 h transfected with siRNAs and corresponding negative control siRNAs, SGC7901, and AGS cells were collected and performed cell cycle assay and cell apoptosis assay in accordance with the manufacture’s protocol (BB-4104, BestBio, China). Flow cytometry assays were performed on the CytoFLEX machine (Beckman, USA). The cell cycle and cell apoptosis distribution were quantified using the CytExpert software.

**Statistical analysis**

For gene expression analysis of different subtypes of GC, the P values were estimated using Mann–Whitney nonparametric test. Survival curves were calculated using the Kaplan–Meier method, and differences between the curves were analyzed using the log-rank test. All the rest of the experiments were used unpaired t-test or one-way ANOVA test. For all experiments, a minimum of triplicates per group and repetition of at least three times was applied to achieve reproducibility. All the gene expression correlation analysis was used spearman test. The regression line was generated by corresponding R package. All tests with P values less than 0.05 considered statistically significant.

**DATA AVAILABILITY**

The datasets generated during the current study are available in the GEO repository (GSE183538).

**REFERENCES**

1. Li DD, Wang JJ, Zhang MX, Hu XH, She JJ, Qiu XM, et al. LncRNA MAG2-AS3 is regulated by BRD4 and promotes gastric cancer progression via maintaining ZEB1 overexpression by sponging miR-141/200a. Mol Ther Nucleic Acids. 2020;19:109–23.
D. Li et al.

2. Wild C, Weiderraps E, Stewart B. World cancer report: cancer research for cancer prevention. Lyon: International Agency for Research on Cancer; 2020. p. 23–33.

3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Cancer J Clin. 2021;71:7–33.

4. Wang JJ, Zhang MX, Hu EH, She JJ, Sun RN, Qin SS, et al. miRNA-194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1. Febio Open Bio. 2021;11:184–26.

5. Cristescu R, Lee J, Nebozyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–U217.

6. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9:1777.

7. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.

8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006;172:973–81.

9. Pastushenko I, Blampain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26.

10. Aiello NM, Kang YB. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216:1016–26.

11. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.

12. Li DD, Cheng P, Wang JJ, Qiu XM, Zhang XD, Xu L, et al. IRF6 is directly regulated by ZEB1 and ELF3, and predicts a favorable prognosis in gastric cancer. Front Oncol. 2019;9:220.

13. Yang X, Liang X, Zheng M, Tang Y. Cellular phenotype plasticity in cancer dormancy and metastasis. Front Oncol. 2018;8:505.

14. Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128–34.

15. Cristescu R, Lee J, Nebozyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449–56.

16. Watanabe K, Liu Y, Noguchi S, Murray M, Chang JC, Kishima M, et al. OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages. Sci Rep. 2019;9:6490.

17. Chen LL. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761–72.

18. Zhang Q, Li T, Wang Z, Kuang X, Shao N, Lin Y. IncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway. J Cell Mol Med. 2020;24:8236–47.

19. Guo F, Fu Q, Wang Y, Sui G. Long non-coding RNA NR2F1-AS1 promoted proliferation and migration yet suppressed apoptosis of thyroid cancer cells through regulating miRNA-338-3p/CCND1 axis. J Cell Mol Med. 2019;23:5907–19.

20. Zhang C, Wu S, Song R, Liu C. Long noncoding RNA NR2F1-AS1 promotes the malignancy of non-small cell lung cancer via sponging microRNA-493-5p and thereby increasing ITGB1 expression. Aging. 2020;13:7660–70.

21. Li DD, She JJ, Hu XH, Zhang MX, Sun RN, Qin SS. The ELF3-regulated IncRNA UBEC2P3 is over-stabilized by RNA-rrNA interactions and drives gastric cancer metastasis via miR-138-5p/TGFα2 axis. Oncogene. 2021;40:5403–15.

22. Chan JJ, Tay Y. Noncoding RNA: regulatory networks in cancer. Int J Mol Sci. 2018;19:11310.

23. Tokumaru Y, Oishi M, Huyser MR, Yan L, Fukada M, Matushashi N, et al. Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer. Sci Rep-Uk. 2021;11:1–11.

24. Chen L, Xiao H, Wang ZH, Huang Y, Liu ZP, Ren H, et al. miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A. Bmb Rep. 2014;47:39–49.

25. Cui Y, Su WY, Xing J, Wang YC, Wang P, Chen XY, et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. Plod One. 2011;6:e25872.

26. Han SC, Wang Z, Liu JN, Wang HM, Yuan YQ, miR-29a-3p-dependent COL3A1 and COL5A1 expression reduction assists sulforaphane to inhibit gastric cancer progression. Biochem Pharmacol. 2021;188:114539.

27. Luo S, Lu YY, Liu LC, Yin YF, Chen CY, Han X, et al. Divergent IncRNAs regulate gene expression and lineage differentiation in pluripotent cells. Cell Stem Cell. 2016;18:637–52.

28. Wang HX, Shi YJ, Chen CH, Wen Y, Zhou ZM, Yang CY, et al. Fulton-induced IncRNA IGF1L1-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGF1. Cancer Lett. 2021;515:49–62.

29. Bryzgalov O, Szczesniak MW, Makalowska I. Retroposition as a source of antisense long non-coding RNAs with possible regulatory functions. Acta Biochim Pol. 2016;63:825–33.

30. Baque-Sastre R, Soler M, Oliveira-Mateos C, Portela A, Moutinho C, Sayols S, et al. Head-to-head antisense transcription and R-loop formation promotes transcriptional activation. Proc Natl Acad Sci USA. 2015;112:5785–90.

31. Heilmann K, Toth R, Bossmann C, Klimo K, Plass C, Gerhauser C. Genome-wide screen for differentially methylated long noncoding RNAs identifies Esrp2 and IncRNA Esrp2p-as regulated by enhancer DNA methylation with prognostic relevance for human breast cancer. Oncogene. 2017;36:6446–61.

32. Berghoff EG, Clark MF, Chen S, Cajigas I, Leib DE, Kohtz JD. Esr2 (Dlx5as) IncRNA regulates ultraconserved enhancer methylation and the differential transcriptional control of adjacent genes. Development. 2013;140:4407–16.

33. Zhang XD, Huang GW, Xie YH, He JZ, Guo JC, Xu XE, et al. The interaction of IncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells. Nucleic Acids Res. 2018;46:1793–809.

34. Zhang YW, Zheng AP, Xu RP, Zhou FY, Hao AL, Yang HJ, et al. NR2F1-induced NR2F1-AS1 promotes esophageal squamous cell carcinoma progression via activating Hedgehog signaling pathway. Biochem Biophys Res Comm. 2019;519:497–504.

35. Feng MY, Wang K, Shi QT, Yu XW, Geng JS. Gene expression profiling in TWIST-depleted gastric cancer cells. Anat Rec. 2009;292:262–70.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (81802375 to Shanshan Qin); the Faculty Development Grants from Hubei University of Medicine (2016QDZJR07 to Dandan Li, 2017QDZJR05 to Shanshan Qin, 2020QDZJR02 to Congcong Huang and 2020QDZJR012 to Pan Huang). We are very grateful to Dr. Jiwei Li (UfLgenes Biotechnology, Shanghai, China) for contributing to the RNA-Seq analysis.

AUTHOR CONTRIBUTIONS

QSS designed experiments, offered direction and help on the whole project. LDD, XJ, WZD, HP, HCC, CMY, ZXJ, and CZ conducted the experiments, analyzed the results, QSS, LDD, and TGF performed bioinformatics analysis. QSS and LDD drafted the manuscript. QSS and LDD reviewed the manuscript and made significant revisions on the drafts. All authors read and approved the final manuscript.

ETHICS STATEMENT

The study is approved by the Ethics Committee of Hubei University of Medicine (2018-TH-035). All participants provided written informed consent. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04540-2.

Correspondence and requests for materials should be addressed to Shanshan Qin.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.